Nuveen’s Genesis Healthcare, Inc. GEN Stock Holding History

Nuveen’s Portfolio GEN Stock Details GEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-576,418	Closed	-$486K	–	3417
2020 Q1	$486K	Sell	576,418 -46,918	-8%	-$67K	﹤0.01%	2782
2019 Q4	$1.02M	Sell	623,336 -12,346	-2%	-$18.5K	﹤0.01%	2679
2019 Q3	$705K	Buy	635,682 +33,668	+6%	+$38.9K	﹤0.01%	2828
2019 Q2	$746K	Buy	+602,014	New	+$766K	﹤0.01%	2862

Other funds holding GEN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

V3 Capital Management Dallas, Texas $33.4M AUM 5.9% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Nuveen's GEN Position: Q2 2020 in Review

Nuveen sold out of Genesis Healthcare, Inc. (GEN) in Q2 2020, closing a stake of 576,418 shares — an estimated $486K sold.

Nuveen first reported a position in GEN in Q2 2019 and held it in 4 quarters. The position peaked at $1.02M in Q4 2019. 58 funds tracked by Wall St. Rank hold GEN as of Q2 2020.

Nuveen reported no remaining Genesis Healthcare, Inc. position as of Q2 2020 after selling out during the quarter.
Nuveen sold 576,418 Genesis Healthcare, Inc. shares in Q2 2020, an estimated $486K.
Nuveen first reported a position in Genesis Healthcare, Inc. in Q2 2019 and held it in 4 quarters.
Nuveen's Genesis Healthcare, Inc. position peaked at $1.02M in Q4 2019.
58 funds tracked by Wall St. Rank held Genesis Healthcare, Inc. as of Q2 2020.

Based on Nuveen's 13F filing for Q2 2020, filed 14 Aug 2020.